BG Medicine and Abbott to Develop Galectin-3 Test for the i-STAT® System - Gilde Healthcare

BG Medicine and Abbott to Develop Galectin-3 Test for the i-STAT® System

March 8, 2010

Waltham, MA—BG Medicine, Inc. today announced that it has entered into an agreement with Abbott Laboratories (NYSE: ABT) to extend its current development and commercialization collaboration to include the development of a galectin-3 test for Abbott Point of Care’s i-STAT System. Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure.
 
Under the agreement, Abbott will be responsible for the development of the test in accordance with certain plans and milestones, and BG Medicine and Abbott will collaborate in support of regulatory filings and studies to support the clinical utility of galectin-3 in the management of patients with acute decompensated heart failure.

“Heart failure is one of the most costly medical conditions. Despite important advances in diagnosis, there remain significant unmet needs in assessing patients with heart failure and selecting a course of action both in emergency room and non-acute care settings,”

said Pieter Muntendam, M.D., President and CEO of BG Medicine.

“This collaboration is an important step toward determining the exact role this test can play in assisting physicians in their efforts to improve outcomes and reduce cost of care.”

About BG Medicine (www.BG-Medicine.com)
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine’s proprietary technology platform enables rapid and cost effective discovery of new high?value diagnostics biomarkers over a broad range of therapeutic areas.

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022